P

Poolbeg Pharma PLC
LSE:POLB

Watchlist Manager
Poolbeg Pharma PLC
LSE:POLB
Watchlist
Price: 4.3 GBX 10.26% Market Closed
Market Cap: 30m GBX

Poolbeg Pharma PLC
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Poolbeg Pharma PLC
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
P
Poolbeg Pharma PLC
LSE:POLB
EPS (Diluted)
£0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
EPS (Diluted)
£1
CAGR 3-Years
-27%
CAGR 5-Years
1%
CAGR 10-Years
-4%
AstraZeneca PLC
LSE:AZN
EPS (Diluted)
$6
CAGR 3-Years
66%
CAGR 5-Years
26%
CAGR 10-Years
16%
Verona Pharma PLC
NASDAQ:VRNA
EPS (Diluted)
$0
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
EPS (Diluted)
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
EPS (Diluted)
$1
CAGR 3-Years
4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
No Stocks Found

Poolbeg Pharma PLC
Glance View

Market Cap
30m GBX
Industry
Pharmaceuticals

Poolbeg Pharma Plc is a clinical-stage infectious disease pharmaceutical company. The firm is focused on targeting the medical needs to treat and prevent infectious disease. The firm's portfolio includes POLB 001, Vaccine Discovery Platform, PredictViral Biomarker Platform, and disease progression data and bio banks. The firm's lead product pipeline candidate is POLB 001. POLB 001 is a Phase II ready p38 mitogen-activated protein kinase (MAPK) inhibitor that reduces harmful inflammation (cytokine storm) in patients with severe influenza. POLB 001 is a repositioned small molecule immunomodulator for severe influenza. The firm is developing a PredictViral biomarker platform, which is used to identify those at risk of developing severe disease. The Vaccine Discovery Platform is a platform used to identify vaccine candidates by isolating protective elements of the naturally occurring immune response.

POLB Intrinsic Value
1.12 GBX
Overvaluation 74%
Intrinsic Value
Price
P

See Also

What is Poolbeg Pharma PLC's EPS (Diluted)?
EPS (Diluted)
-0 GBP

Based on the financial report for Dec 31, 2024, Poolbeg Pharma PLC's EPS (Diluted) amounts to -0 GBP.

What is Poolbeg Pharma PLC's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 1Y
0%

Over the last year, the EPS (Diluted) growth was 0%.

Back to Top